WallStSmart

Mangoceuticals, Inc. Common Stock (MGRX)vsMiniMed Group, Inc. Common Stock (MMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 618006% more annual revenue ($2.89B vs $466,910). MGRX leads profitability with a 0.0% profit margin vs -7.3%. MMED earns a higher WallStSmart Score of 37/100 (F).

MGRX

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 2.04

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MGRX2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

MMED0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MGRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.27M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MGRX

The strongest argument for MGRX centers on Price/Book, Debt/Equity.

Bull Case : MMED

Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : MGRX

The primary concerns for MGRX are EPS Growth, Market Cap, Profit Margin.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Key Dynamics to Monitor

MGRX profiles as a value stock while MMED is a turnaround play — different risk/reward profiles.

MMED is growing revenue faster at 13.1% — sustainability is the question.

MGRX generates stronger free cash flow (-1M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MMED scores higher overall (37/100 vs 24/100) and 13.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Mangoceuticals, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Mangoceuticals, Inc. focuses to develop, market, and sell various men's wellness products and services through a telemedicine platform. The company is headquartered in Dallas, Texas.

Visit Website →

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Want to dig deeper into these stocks?